CN115868628A - Weight-reducing composition - Google Patents
Weight-reducing composition Download PDFInfo
- Publication number
- CN115868628A CN115868628A CN202211239020.5A CN202211239020A CN115868628A CN 115868628 A CN115868628 A CN 115868628A CN 202211239020 A CN202211239020 A CN 202211239020A CN 115868628 A CN115868628 A CN 115868628A
- Authority
- CN
- China
- Prior art keywords
- nadh
- vitamin
- weight
- source
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 57
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims abstract description 57
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229910001425 magnesium ion Inorganic materials 0.000 claims abstract description 22
- 230000002503 metabolic effect Effects 0.000 claims abstract description 21
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 claims abstract description 20
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 20
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 20
- 210000003205 muscle Anatomy 0.000 claims abstract description 16
- 230000004102 tricarboxylic acid cycle Effects 0.000 claims abstract description 14
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 24
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 16
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 16
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 13
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 12
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 12
- 235000019158 vitamin B6 Nutrition 0.000 claims description 12
- 239000011726 vitamin B6 Substances 0.000 claims description 12
- 229940011671 vitamin b6 Drugs 0.000 claims description 12
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 11
- 229930003268 Vitamin C Natural products 0.000 claims description 11
- 235000019154 vitamin C Nutrition 0.000 claims description 11
- 239000011718 vitamin C Substances 0.000 claims description 11
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 10
- 229930003779 Vitamin B12 Natural products 0.000 claims description 10
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims description 10
- 150000004676 glycans Chemical class 0.000 claims description 10
- 229920001282 polysaccharide Polymers 0.000 claims description 10
- 239000005017 polysaccharide Substances 0.000 claims description 10
- 229960002477 riboflavin Drugs 0.000 claims description 10
- 229960003495 thiamine Drugs 0.000 claims description 10
- 235000019163 vitamin B12 Nutrition 0.000 claims description 10
- 239000011715 vitamin B12 Substances 0.000 claims description 10
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 9
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 8
- 229960002685 biotin Drugs 0.000 claims description 8
- 235000020958 biotin Nutrition 0.000 claims description 8
- 239000011616 biotin Substances 0.000 claims description 8
- 239000002702 enteric coating Substances 0.000 claims description 8
- 238000009505 enteric coating Methods 0.000 claims description 8
- 229960000304 folic acid Drugs 0.000 claims description 8
- 235000019152 folic acid Nutrition 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 229960003512 nicotinic acid Drugs 0.000 claims description 8
- 230000004580 weight loss Effects 0.000 claims description 8
- 229930003451 Vitamin B1 Natural products 0.000 claims description 7
- 229930003471 Vitamin B2 Natural products 0.000 claims description 7
- 229930003537 Vitamin B3 Natural products 0.000 claims description 7
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008518 lycium barbarum polysaccharide Substances 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- 235000010374 vitamin B1 Nutrition 0.000 claims description 7
- 239000011691 vitamin B1 Substances 0.000 claims description 7
- 235000019164 vitamin B2 Nutrition 0.000 claims description 7
- 239000011716 vitamin B2 Substances 0.000 claims description 7
- 235000019160 vitamin B3 Nutrition 0.000 claims description 7
- 239000011708 vitamin B3 Substances 0.000 claims description 7
- 239000004386 Erythritol Substances 0.000 claims description 6
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 6
- 229960003624 creatine Drugs 0.000 claims description 6
- 239000006046 creatine Substances 0.000 claims description 6
- 229940009714 erythritol Drugs 0.000 claims description 6
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 6
- 235000019414 erythritol Nutrition 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 4
- 229930189775 mogroside Natural products 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 229940056905 magnesium l-threonate Drugs 0.000 claims description 3
- YVJOHOWNFPQSPP-BALCVSAKSA-L magnesium;(2r,3s)-2,3,4-trihydroxybutanoate Chemical compound [Mg+2].OC[C@H](O)[C@@H](O)C([O-])=O.OC[C@H](O)[C@@H](O)C([O-])=O YVJOHOWNFPQSPP-BALCVSAKSA-L 0.000 claims description 3
- 244000185386 Thladiantha grosvenorii Species 0.000 claims description 2
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 claims description 2
- 229930182470 glycoside Natural products 0.000 claims description 2
- 150000002338 glycosides Chemical class 0.000 claims description 2
- 208000016261 weight loss Diseases 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims 2
- 244000241838 Lycium barbarum Species 0.000 claims 1
- 235000015459 Lycium barbarum Nutrition 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 abstract description 38
- 230000000694 effects Effects 0.000 abstract description 15
- 230000007246 mechanism Effects 0.000 abstract description 7
- 239000002994 raw material Substances 0.000 abstract description 5
- 206010050637 Skin tightness Diseases 0.000 abstract description 3
- 230000006866 deterioration Effects 0.000 abstract description 3
- 230000004089 microcirculation Effects 0.000 abstract description 3
- 230000037394 skin elasticity Effects 0.000 abstract description 3
- 239000003925 fat Substances 0.000 description 18
- 210000003491 skin Anatomy 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000007102 metabolic function Effects 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 235000018927 edible plant Nutrition 0.000 description 5
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 3
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229960003180 glutathione Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000037219 healthy weight Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000003470 mitochondria Anatomy 0.000 description 3
- 230000004898 mitochondrial function Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 235000013406 prebiotics Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000001243 protein synthesis Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 235000019157 thiamine Nutrition 0.000 description 3
- 239000011721 thiamine Substances 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 229960004203 carnitine Drugs 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000037323 metabolic rate Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000001483 mobilizing effect Effects 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000000276 sedentary effect Effects 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 102000040350 B family Human genes 0.000 description 1
- 108091072128 B family Proteins 0.000 description 1
- 102000016680 Dioxygenases Human genes 0.000 description 1
- 108010028143 Dioxygenases Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010020056 Hydrogenase Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000006567 cellular energy metabolism Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 230000004136 fatty acid synthesis Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 125000003929 folic acid group Chemical group 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 235000021332 kidney beans Nutrition 0.000 description 1
- 235000020997 lean meat Nutrition 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000037345 metabolism of vitamins Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 239000002719 pyrimidine nucleotide Substances 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a weight-losing composition, which comprises tricarboxylic acid cycle functional factors, a metabolism promoter, a metabolism synergist and a muscle promoter; the tricarboxylic acid cycle function factors include a source of NADH, lipoic acid, and a source of magnesium ions; the metabolic synergist comprises PQQ; the mass ratio of the NADH source to the lipoic acid to the magnesium ion source to the PQQ is 10-80: 50 to 300:10 to 300:10 to 20. The weight-losing composition simulates the mechanism of exercise weight-losing through reasonable collocation and formula of raw materials, can improve the metabolic level and metabolic capability of an organism after being taken, achieves the effect of exercise weight-losing, namely healthy weight-losing, simultaneously accelerates skin microcirculation, achieves the effects of skin tightness, skin brightness and the like, and avoids the conditions of skin elasticity deterioration, relaxation or collapse caused by weight-losing.
Description
Technical Field
The invention relates to the field of health care products, in particular to a weight-losing composition.
Background
The traditional weight-reducing product or weight-reducing method generally increases the consumption of fat during exercise by L-carnitine, achieves satiety and reduces calorie intake by dietary fiber, and achieves the purpose of reducing weight by blocking the absorption of starch by components such as white kidney beans and excreting components such as anthrone.
The traditional weight-reducing products achieve the purpose of reducing weight not by improving metabolic syndrome of human bodies, and the weight-reducing method which cannot improve metabolic syndrome is unsafe and unscientific.
The principle of healthy weight loss is to lose weight by increasing metabolic levels. The decrease in fat metabolic rate is the root cause of obesity, which has been classified as a metabolic disease in modern medicine. Therefore, the key to healthy weight loss is to improve metabolic capacity, which is also the mechanism of healthy weight loss. A study published in the United states daily medical journal of 2016 showed that: the skin can be kept young and even the aging process of the skin can be reversed by doing regular exercise for a certain period of time every week. The results show that in persons of the same age group, the skin stratum corneum thickness of the skin was thinner in the sports group than in the sedentary group, and the mitochondrial content of the skin tissue was higher in the sedentary group. The stratum corneum of the skin is thin, and the number of mitochondria contained in skin cells is large and active, which is just the appearance of young skin. In other words, exercise for losing weight can not only improve metabolism level, but also reverse skin aging and keep young.
On the basis, the weight-losing effect similar to exercise is achieved by simulating the mechanism of exercise weight-losing, so that the purpose of losing weight is achieved, and the possibility is achieved. There is no weight loss composition in the prior art that mimics the mechanism of exercise weight loss.
Disclosure of Invention
Based on this, there is a need for a weight loss composition that mimics the mechanisms of exercise weight loss.
A composition for reducing weight comprises tricarboxylic acid cycle functional factor, metabolism promoter, metabolism synergist and muscle promoter; wherein the tricarboxylic acid cycle functional factors comprise NADH source, lipoic acid and magnesium ion source, and the mass ratio of the NADH source to the lipoic acid to the magnesium ion source is 10-80: 50 to 300:10 to 300.
In one embodiment, the metabolic synergist comprises PQQ and the source of magnesium ions is magnesium L-threonate; the mass ratio of the NADH source to the PQQ is 10-80: 10 to 20.
In one embodiment, the mass ratio of said source of NADH to said muscle promoter is from 10 to 80:300 to 1500.
In one embodiment, the muscle-building agent is creatine.
In one embodiment, the metabolism-promoting agent comprises trimethylglycine, vitamin C, and a plant polysaccharide having a β -glycosidic bond that is homologous to food and drug.
In one embodiment, the medicinal and edible plant polysaccharide with beta-glycosidic bond comprises pachyman and lycium barbarum polysaccharide;
the mass ratio of the NADH source, the trimethylglycine, the vitamin C, the pachyman and the lycium barbarum polysaccharide is (10-80): 200 to 5000:50 to 500: 200-5000: 200 to 800.
In one embodiment, the NADH source is NADH enteric powder, the NADH enteric powder includes NADH and an enteric coating coated on the NADH, and the mass ratio of the NADH to the enteric coating is 10-30: 70 to 90.
In one embodiment, the metabolic synergist further comprises B vitamins including vitamin B1, vitamin B3, vitamin B2, vitamin B6, biotin, folic acid and vitamin B12.
In one embodiment, the mass ratio of said NADH source, said vitamin B1, said vitamin B3, said vitamin B2, said vitamin B6, said biotin, said folic acid and said vitamin B12 is 10-80: 2 to 20:4 to 30:2 to 20:2 to 10:5 to 20: 0.06-0.4: 0.004-0.012.
In one embodiment, further comprising a flavoring agent comprising erythritol, mogrosides, and fruit powder;
the mass ratio of the NADH source to the erythritol to the momordica grosvenori glycoside to the fruit powder is 10-80: 500-5000: 20 to 100:1000 to 5000.
The slimming composition comprises tricarboxylic acid cycle functional factor, metabolism promoter, metabolism synergist and muscle promoter; the NADH source, the lipoic acid and the magnesium ions are used as main functional factors of the tricarboxylic acid cycle to realize the synergistic effect, so that the metabolic function of the organism is improved, the whole body can pass through without obstruction, any cell part can be reached, the comprehensive effect of the human body can be provided, the channels and collaterals of the whole body can be dredged, the nutrition can be smoothly delivered to each tissue cell, the metabolites of each tissue cell can be eliminated, and the normal work of each body function can be mobilized. The metabolism synergist, particularly PQQ, can improve the mitochondrial function, B vitamins assist the metabolic function to be smoothly carried out, the basic metabolic function of a human machine can be well improved, the metabolism promoter promotes the metabolism of fat and protein and accelerates the catabolism of triglyceride, and the mass ratio of the NADH source to the lipoic acid to the magnesium ion source to the PQQ is 10-80: 50-300: 10 to 300:10 to 20, can achieve the optimal function of mobilizing the body functions.
The weight-losing composition simulates the mechanism of exercise weight-losing through the innovative collocation and proportion of various raw materials, can improve the metabolic level and metabolic capability of an organism after being taken, achieves the effect of exercise weight-losing, namely healthy weight-losing, and simultaneously accelerates the microcirculation of skin, achieves the effects of skin tightness, skin brightness and the like, and avoids the situations of skin elasticity deterioration, relaxation or collapse caused by weight-losing.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The invention discloses a weight-reducing composition of an embodiment, which comprises tricarboxylic acid cycle functional factors, metabolism promoters, metabolism synergists and muscle promoters; wherein the tricarboxylic acid cycle functional factors comprise an NADH source, lipoic acid and a magnesium ion source, and the mass ratio of the NADH source to the lipoic acid to the magnesium ion source is 10-80: 50 to 300:10 to 300.
The slimming composition comprises tricarboxylic acid cycle functional factor, metabolism promoter, metabolism synergist and muscle promoter; the NADH source, the lipoic acid and the magnesium ions are used as main functional factors of the tricarboxylic acid cycle to act synergistically, so that the metabolic function of the organism is improved, the whole body can pass through without hindrance and reach any cell part, the comprehensive efficiency of the human body is provided, the nutrition can be smoothly delivered to each tissue cell like dredging the channels and collaterals of the whole body, the metabolites of each tissue cell are eliminated, and the normal work of each body function is mobilized. The metabolism synergist, particularly PQQ, can improve the mitochondrial function, B vitamins assist the metabolic function to be smoothly carried out, the basic metabolic function of a human machine can be well improved, the metabolism promoter promotes the metabolism of fat and protein and accelerates the catabolism of triglyceride, and the mass ratio of the NADH source to the lipoic acid to the magnesium ion source to the PQQ is 10-80: 50-300: 10 to 300: 10-20, can achieve the best function of mobilizing the body functions.
The weight-losing composition simulates the mechanism of exercise weight-losing through the innovative matching and proportioning of various raw materials, can improve the metabolic level and metabolic capability of an organism after being taken, achieves the effect of exercise weight-losing, namely healthy weight-losing, and simultaneously accelerates the microcirculation of skin, achieves the effects of skin tightness, skin brightness and the like, and avoids the situations of skin elasticity deterioration, looseness or collapse caused by weight-losing.
The weight-reducing composition can reduce fat and weight and keep skin compact and fine.
In particular, NADH, also known as mitochondrial, is a coenzyme essential for cellular energy metabolism and is involved in glycolysis, the tricarboxylic acid cycle, oxidative phosphorylation, liberating protons and electrons, providing energy for ATP synthesis. It can promote the synthesis and metabolism of nucleic acid, protein and polysaccharide, raise oxygen utilization, increase muscle energy supply and shorten reaction time, and is used as the material for regulating body's metabolism. And meanwhile, NADH can regenerate oxidized coenzyme Q10, glutathione and the like, so that the oxidized coenzyme Q10, the glutathione and the like recover the oxidation resistance, part of free radicals generated by metabolism are removed, and the anti-aging effect of the organism is achieved.
In particular, lipoic acid is a coenzyme present in mitochondria, like vitamins. Lipoic acid is a cofactor of pyruvate dehydrogenase complex, ketoglutarate and amino acid hydrogenase complex, and can promote the utilization of glucose and accelerate the metabolism of carbohydrates. The lipoic acid enters cells after being absorbed by intestinal tracts in vivo, and has the characteristics of fat solubility and water solubility, so the lipoic acid can pass through the whole body without resistance and reach any cell part, thereby providing comprehensive efficiency for the human body. The lipoic acid can promote the regeneration of vitamin C and vitamin E, increase glutathione and coenzyme Q10 in cells, and synergistically cooperate with NADH to achieve the effects of resisting oxidation and eliminating free radicals, promote recovery and improve the capability of increasing muscles and reducing fat of a human body.
The magnesium ion source is used for providing magnesium ions, and the magnesium ions can activate fatty acid and activate the activities of various enzymes of a human body. Magnesium ions also function to maintain bone growth and neuromuscular excitability, to maintain gastrointestinal tract and hormones.
The NADH source, the lipoic acid and the magnesium ions are used as main functional factors of the tricarboxylic acid cycle, and the three have synergistic effect to mainly improve the metabolic function of the organism, so that the whole body can pass through without obstruction and reach any cell part, thereby providing the comprehensive efficiency of the human body.
Preferably, in this embodiment, the metabolic synergist comprises PQQ and the source of magnesium ions is magnesium L-threonate.
In the invention, the mass ratio of the NADH source to the lipoic acid to the magnesium ion source to the PQQ is 10-80: 50-300: 10 to 300:10 to 20.
PQQ can improve existing mitochondrial function, promote regeneration of new mitochondria, increase body energy levels, increase attention, and reverse senescence from the cellular level. PQQ may benefit diseases of mitochondrial dysfunction, including metabolic disorders. PQQ has similar metabolic kinetics as the B family of vitamins and does not accumulate in large amounts in the body.
Preferably, in this embodiment, the mass ratio of the NADH source to the muscle promoter is 10 to 80:300 to 1500.
Preferably, in this embodiment, the muscle promoter is creatine.
Creatine, which is a safe and effective nutrient used in sports nutrition in a mature state, has a substance synthesized from three amino acids, arginine (arginine), glycine (glycine) and methionine (methionine). Creatine is an amino acid derivative naturally produced in human body, and can rapidly increase muscle strength, promote the growth of new muscle, accelerate fatigue recovery and improve explosive force. The more creatine is stored in human body, the stronger the strength and the athletic ability are.
Preferably, in the embodiment, the metabolism promoter further comprises trimethylglycine, vitamin C and a polysaccharide of a plant having a β -glycosidic bond and being edible and pharmaceutical.
The trimethylglycine can regulate in-vivo osmotic pressure, relieve stress, promote fat metabolism and protein synthesis, improve lean meat percentage, increase muscle and reduce fat.
The vitamin C has positive effects on promoting liver fat metabolism and pancreas fat metabolism, and can be used for reducing weight of the composition to effectively reduce visceral fat content.
Vitamin C is involved in carnitine synthesis, and vitamin C-dependent dioxygenases are affected by vitamin C deficiency, which requires two AADs for carnitine synthesis. Vitamin C also reduces serum and liver triglyceride levels, and reduces liver free fatty acids.
The medicinal and edible plant polysaccharide with beta-glycosidic bond can be developed into characteristic prebiotics of medicinal and edible plants, and can improve insulin resistance and regulate blood sugar and blood fat through intestinal flora.
The medicinal and edible plant polysaccharide with beta-glycosidic bond not only has the function of conditioning intestines and stomach by prebiotics, but also has the function of repairing inflammatory factors, promotes the smooth metabolism by healthy intestines and stomach, simultaneously promotes the body metabolism and updates the cell health by the free radical removal of antioxidant raw materials, and the skin is compact and fine.
In particular, the medicinal and edible plant polysaccharide with beta-glycosidic bond comprises pachymaran and lycium barbarum polysaccharide.
Pachyman can be used as prebiotics for preventing and treating metabolic diseases.
The lycium barbarum polysaccharide has the functions of enhancing immunity and regulating immunity, promoting hematopoiesis, and reducing blood fat, resisting fatty liver, resisting tumor, resisting aging and the like.
The pachyman and the lycium barbarum polysaccharide are matched, so that the metabolic function of the body can be effectively and continuously and healthily operated.
The mass ratio of NADH source, trimethylglycine, vitamin C, pachymaran and lycium barbarum polysaccharide is 10-80: 200-5000: 50 to 500: 200-5000: 200 to 800.
In the embodiment, the NADH source is NADH enteric-coated powder, which comprises NADH and an enteric coating coated outside the NADH, wherein the mass ratio of the NADH to the enteric coating is 10-30: 70 to 90. In other embodiments, the specific mass ratio may be set according to actual requirements.
In the present invention, the enteric coating is insoluble in the mouth and stomach and soluble in the small intestine, thereby ensuring that NADH in the NADH enteric powder can be released in the small intestine.
The specific components of the enteric coating and the specific preparation method of the NADH enteric powder can refer to CN 113440497A-microcapsule powder stable in gastric acid and the preparation method and application thereof.
Preferably, in this embodiment, the B vitamins include vitamin B1, vitamin B3, vitamin B2, vitamin B6, biotin, folic acid, and vitamin B12.
Vitamin B1, also known as thiamine, plays an important role in the metabolism of animal sugars, for example, pyruvate requires thiamine in the case of decarboxylation and TPP-catalyzed enzymatic reactions also require the presence of magnesium ions. Thiamine participates in sugar metabolism, so that normal digestion of a human body can be maintained, and the effect of delaying skin aging is achieved.
Vitamin B3 plays a role in hydrogen delivery in the biooxidative respiratory chain, can promote the biooxidative process and tissue metabolism, and has an important role in maintaining the integrity of normal tissues (particularly skin, digestive tract and nervous system).
Vitamin B2, also known as riboflavin, is involved in biological oxidation and energy metabolism in vivo, is involved in the metabolism of carbohydrates, proteins, nucleic acids and fats, and can improve the utilization rate of protein by the body, promote growth and development, and maintain the integrity of skin and cell membranes. Has effects in protecting hair follicle, mucosa and sebaceous gland of skin. Riboflavin is involved in the growth and metabolism of cells, and is an essential nutrient for the metabolism and repair of body tissues, such as strengthening the liver function and regulating the secretion of adrenaline. Riboflavin is involved in the metabolism of vitamin B6 and nicotinic acid, and is a model of the coordination of B vitamins.
Vitamin B6 is an essential substance for human fat and sugar metabolism, and vitamin B6 is also required for estrogen metabolism in women. Vitamin B6 is involved in protein synthesis and catabolism, and in all amino acid metabolism. Vitamin B6 is involved in gluconeogenesis and UFA metabolism. Vitamin B6 is also involved in the metabolism of glycogen, sphingomyelin and steroids.
Biotin is a key regulatory element for glycogen catabolism, fatty acid synthesis and metabolism of certain amino acids, and can promote the synthesis of certain proteins by aiding energy production. Biotin aids in cell growth, production of fatty acids, metabolic carbohydrates, fats and proteins, and facilitates the utilization of vitamin B groups.
Folic acid is a substance necessary for human body to utilize sugar and amino acids, and is a substance necessary for growth and reproduction of body cells. Folic acid functions in vivo in the form of tetrahydrofolic acid, which is involved in the synthesis and conversion of purine and pyrimidine nucleotides in vivo.
Vitamin B12 promotes the development and maturation of erythrocytes, maintains the hematopoietic function of the body in a normal state, prevents pernicious anemia, and maintains the health of the nervous system. The vitamin B12 exists in the form of coenzyme, and can increase the utilization rate of folic acid and promote the metabolism of carbohydrate, fat and protein. Vitamin B12 has the functions of activating amino acid, promoting nucleic acid biosynthesis and protein synthesis, and has important effect on infant growth. Vitamin B12 metabolizes fatty acids, allowing fats, carbohydrates, and proteins to be properly utilized by the body.
In one embodiment, the mass ratio of NADH source, vitamin B1, vitamin B3, vitamin B2, vitamin B6, biotin, folic acid and vitamin B12 is 10 to 80:2 to 20:4 to 30:2 to 20:2 to 10:5 to 20: 0.06-0.4: 0.004-0.012.
Preferably, in this embodiment, the food further comprises a flavoring agent, wherein the flavoring agent comprises erythritol, mogroside and fruit powder.
The fruit powder can be blueberry fruit powder or fruit powder with other tastes.
In the embodiment, the mass ratio of the NADH source, the erythritol, the mogroside to the fruit powder is 10-80: 500 to 5000:20 to 100:1000 to 5000.
The weight-reducing composition of this embodiment may be formulated into powder, the content of each portion being 5g, and each portion is taken every three hours, and four portions are taken every day. The continuous basal high metabolic rate is achieved by intermittent administration, so that the basal metabolism of a human body reaches the optimal state all day.
The following are specific examples. The NADH source is NADH enteric-coated powder, the NADH enteric-coated powder is rice bran fatty alkanol coated NADH, and the mass ratio of the rice bran fatty alkanol to the NADH is 8:2.
example 1
Table 1: formula of weight-losing composition
According to the above table 1, the raw materials of the components are weighed and mixed into powder to obtain the weight-reducing composition, wherein the content of each part is 5g.
Comparative example 1
Comparative example 1 was substantially identical to the composition of example 1 except that NADH enteric powder was removed.
Comparative example 2
Comparative example 1 was substantially the same as the components of example 1 except that lipoic acid was removed.
Test example
Comparison with the efficacy of moderate intensity sports
Overweight obese people 120 were screened, 60 men and women, randomly divided into four groups of 30 people each and ensured that the number of men and women in each group was the same, and the BMI values are shown in table 2 below.
TABLE 2
Group 1 the diet composition obtained in example 1 was taken daily, one portion every three hours and four portions a day; group 2, taking the weight-reducing composition obtained in comparative example 1 every day, one part every three hours, four parts a day; group 3 took the slimming composition obtained in comparative example 1 every day, one part every three hours, four parts a day; group 4 performed moderate exercise (700 kcal should be consumed) for 5 days of exercise a week. Four groups of people eat the same diet daily, 2000 KCAL/day for men and 1700 KCAL/day for women, for one week to obtain table 3 below. Wherein the medium intensity movements are referred to table 4.
Table 3: comparison of metabolic data for four groups of people
TABLE 4
As can be seen from table 3, the metabolic data of group 1 and group 4 are comparable, indicating that the weight-reducing composition obtained in example 1 can exert effects similar to those of moderate exercise.
The metabolic data of group 1 were significantly higher than those of groups 2 and 3, indicating that it was difficult to achieve the effect of moderate exercise by taking the diet compositions of groups 2 and 3.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is specific and detailed, but not to be construed as limiting the scope of the claims. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A weight loss composition comprising a tricarboxylic acid cycle functional factor, a metabolic enhancer, a metabolic synergist, and a muscle enhancer;
the tricarboxylic acid cycle functional factor comprises an NADH source, lipoic acid and a magnesium ion source, wherein the mass ratio of the NADH source to the lipoic acid to the magnesium ion source is 10-80: 50 to 300:10 to 300.
2. The weight loss composition of claim 1, wherein the metabolic synergist comprises PQQ and the source of magnesium ions is magnesium L-threonate;
the mass ratio of the NADH source to the PQQ is 10-80: 10 to 20.
3. The slimming composition of claim 1, wherein a mass ratio of said NADH source and said muscle promoter is between 10 and 80:300 to 1500.
4. The slimming composition of claim 3, wherein said muscle promoter is creatine.
5. The weight-loss composition as claimed in claim 3, wherein the metabolism-promoting agent comprises trimethylglycine, vitamin C and a plant polysaccharide having a β -glycosidic bond and being homologous to food.
6. The weight-losing composition as claimed in claim 5, wherein the plant polysaccharides having beta-glycosidic bonds comprise pachyman and Lycium barbarum polysaccharides;
the weight ratio of the NADH source to the trimethylglycine to the vitamin C to the pachyman to the lycium barbarum polysaccharide is 10-80: 200 to 5000:50 to 500:200 to 5000:200 to 800.
7. The weight-reducing composition according to any one of claims 1 to 6, wherein the NADH source is NADH enteric powder, the NADH enteric powder comprises NADH and an enteric coating coated outside the NADH, and the mass ratio of the NADH to the enteric coating is 10 to 30:70 to 90.
8. The slimming composition of claim 7, wherein said metabolic synergist further comprises B vitamins comprising vitamin B1, vitamin B3, vitamin B2, vitamin B6, biotin, folic acid, and vitamin B12.
9. The weight-loss composition as claimed in claim 8, wherein the weight ratio of the NADH source, the vitamin B1, the vitamin B3, the vitamin B2, the vitamin B6, the biotin, the folic acid and the vitamin B12 is 10-80: 2 to 20:4 to 30:2 to 20:2 to 10:5 to 20: 0.06-0.4: 0.004-0.012.
10. The slimming composition of claim 9, further comprising a flavoring agent, said flavoring agent comprising erythritol, mogroside, and fruit powder;
the mass ratio of the NADH source to the erythritol to the momordica grosvenori glycoside to the fruit powder is 10-80: 500-5000: 20 to 100:1000 to 5000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211239020.5A CN115868628B (en) | 2022-10-11 | 2022-10-11 | Weight-reducing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211239020.5A CN115868628B (en) | 2022-10-11 | 2022-10-11 | Weight-reducing composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115868628A true CN115868628A (en) | 2023-03-31 |
| CN115868628B CN115868628B (en) | 2024-01-26 |
Family
ID=85770321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211239020.5A Active CN115868628B (en) | 2022-10-11 | 2022-10-11 | Weight-reducing composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115868628B (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100124587A1 (en) * | 2008-11-17 | 2010-05-20 | Heuer Marvin A | Creatine-containing vitamin and mineral composition |
| CN101791079A (en) * | 2010-03-12 | 2010-08-04 | 苟春虎 | Capsule for reducing weight and beautifying features |
| CN104883911A (en) * | 2013-01-11 | 2015-09-02 | Mjn美国控股有限责任公司 | Nutritional compositions containing magnesium threonate and uses thereof |
| CN106360734A (en) * | 2016-09-28 | 2017-02-01 | 张家港威胜生物医药有限公司 | Composition with both roles of weight losing and facial features beautifying and preparing method and application thereof |
| CN106974933A (en) * | 2017-03-24 | 2017-07-25 | 徐州医科大学 | A kind of topical composition with antiobesity action |
| KR20170101081A (en) * | 2016-02-25 | 2017-09-05 | 오명진 | Parenteral solution for diet containing lipolysis and celluite-improoving ingredient |
| CN108685971A (en) * | 2018-06-12 | 2018-10-23 | 泓博元生命科技（深圳）有限公司 | A kind of Weight reducing compound and its preparation method and application |
| CN110831587A (en) * | 2017-05-12 | 2020-02-21 | 圣胡安德申医院 | Betaine for preventing obesity |
| CN113440497A (en) * | 2021-07-20 | 2021-09-28 | 泓博元生命科技（深圳）有限公司 | Microcapsule powder stable in gastric acid and preparation method and application thereof |
-
2022
- 2022-10-11 CN CN202211239020.5A patent/CN115868628B/en active Active
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100124587A1 (en) * | 2008-11-17 | 2010-05-20 | Heuer Marvin A | Creatine-containing vitamin and mineral composition |
| CN101791079A (en) * | 2010-03-12 | 2010-08-04 | 苟春虎 | Capsule for reducing weight and beautifying features |
| CN104883911A (en) * | 2013-01-11 | 2015-09-02 | Mjn美国控股有限责任公司 | Nutritional compositions containing magnesium threonate and uses thereof |
| KR20170101081A (en) * | 2016-02-25 | 2017-09-05 | 오명진 | Parenteral solution for diet containing lipolysis and celluite-improoving ingredient |
| CN106360734A (en) * | 2016-09-28 | 2017-02-01 | 张家港威胜生物医药有限公司 | Composition with both roles of weight losing and facial features beautifying and preparing method and application thereof |
| CN106974933A (en) * | 2017-03-24 | 2017-07-25 | 徐州医科大学 | A kind of topical composition with antiobesity action |
| CN110831587A (en) * | 2017-05-12 | 2020-02-21 | 圣胡安德申医院 | Betaine for preventing obesity |
| CN108685971A (en) * | 2018-06-12 | 2018-10-23 | 泓博元生命科技（深圳）有限公司 | A kind of Weight reducing compound and its preparation method and application |
| CN113440497A (en) * | 2021-07-20 | 2021-09-28 | 泓博元生命科技（深圳）有限公司 | Microcapsule powder stable in gastric acid and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115868628B (en) | 2024-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6368617B1 (en) | Dietary supplement | |
| CN102762097B (en) | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| CN101248900B (en) | Novel solid sport drink medicinal granules | |
| CN111972672A (en) | Composition with muscle increasing function and application thereof | |
| CA2514687A1 (en) | Advenced vitamin c-based composition with enhanced biotransformation and utilization of protein and l-carnitine for nutritional supplementation or the like | |
| CN103190483A (en) | Children growth promotion milk tea | |
| US20030104107A1 (en) | Energy drink formula and method | |
| CN114711374A (en) | Composite nutrient powder of ferment fibre and its preparation method | |
| JP4526047B2 (en) | Strength enhancer | |
| US20200155589A1 (en) | Composition For Enchanced Recovery After Surgery (ERAS) | |
| CN107223981B (en) | Composition containing soybean polypeptide argatroxin and preparation method thereof | |
| CN101690591A (en) | Yak marrow polypeptide bone growing and height increasing tablets (powder) | |
| CN102273581A (en) | Compound sweetener with high sweetness | |
| CN110742267B (en) | Total-nutrient formula food for inflammatory bowel diseases | |
| CN110584120A (en) | Bone health composition | |
| CN111387486A (en) | Special medical formula nutrition powder for liver disease patients and preparation method thereof | |
| KR101540004B1 (en) | Composition of Health Functional Foods for Improving of Blood sugar, Blood pressure, Blood Circulation and Cholesterol into Blood | |
| CN115868628A (en) | Weight-reducing composition | |
| CN114747720A (en) | Soybean peptide composite powder composition combined powder and preparation method thereof | |
| CN104982768B (en) | A kind of jelly and preparation method thereof of suitable nephropathy patient's energy supplement | |
| CN103330118A (en) | Antiobesity drug | |
| CN106036387A (en) | Super chenopodium quinoa willd nutritional packet for promoting growth of children | |
| CN112690386A (en) | A dietetic composition with antioxidant and antibacterial effects and capable of enhancing cardiovascular and cerebrovascular and immunity | |
| CN112656933B (en) | Parenteral nutrient solution suitable for patients with pneumonia | |
| CN110226756A (en) | Prevention and alleviation type 2 diabetic patient's flesh lack the protein modules and preparation method of disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |